Luminex snaps up EraGen Biosciences in $34M deal

Austin-based Luminex is snapping up EraGen Biosciences for $34 million. The buyout gives Luminex a new portfolio of molecular diagnostic assays that can be put to use as it broadens its own molecular diagnostics work for pharmaceutical drug discovery, clinical diagnostics and biomedical research. The 12-year-old EraGen is based in Madison, WI and has a staff of about 70.

"We are excited by the opportunity to expand our capabilities and product line in the important and rapidly growing infectious disease and molecular diagnostic markets with high growth, high margin, complementary assays," said Patrick J. Balthrop, president and CEO of Luminex.  "The acquisition of EraGen builds on the strategic investments we have made and provides additional resources for sales, support and assay development, strengthening our leadership position and expanding our footprint within the molecular diagnostic market."

EraGen products include the MultiCode-RTx Herpes Simplex Virus 1&2 Kit, the first FDA cleared PCR-based qualitative test for the detection and typing of HSV-1 or HSV-2 from vaginal lesion swab specimens.

- here's the Luminex release

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.